What is SPRO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SPRO?

P/E (TTM) is 9.47 and 52-week range is $1.08 to $3.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SPRO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SPRO?

The company profile lists revenue (TTM) near $47M, net income (TTM) near $12M, EPS (TTM) near $0.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Spero Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 57.9M shares outstanding, ISIN US84833T1034 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Spero Therapeutics Inc

$SPRO

Health Care · Biotechnology

IR Run Scenarios

$1.20

+5.26%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 25 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Website

sperotherapeutics.com/

IPO

2017-11-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)